Deepinder Goyal’s Startup Temple Acquires London Longevity Clinic LongeVus
Wearable technology company Temple, backed by entrepreneur Deepinder Goyal, has completed the acquisition of London-based longevity medicine clinic LongeVus. The move integrates clinical expertise directly into Temple as the startup prepares its physiological sensor technology for an upcoming commercial rollout.
What Happened
Temple has acquired LongeVus for an undisclosed amount, bringing the longevity clinic’s founders into executive leadership roles at the startup. Robert Mohr joins as chief medical officer, while Avi Roy takes on the role of head of science. LongeVus will remain operational under Temple, allowing its founders to continue providing services to existing clientele.
The acquisition follows a two-month trial period during which Mohr and Roy tested Temple’s head-worn device. The founders worked alongside the company’s research team to examine its physiological monitoring capabilities and evaluate its proprietary “Entropy” metric before formally assisting in broader scientific validation efforts.
Key Highlights
- Leadership additions: LongeVus co-founders Robert Mohr and Avi Roy join Temple as chief medical officer and head of science, respectively.
- Device functionality: Temple’s wearable hardware sits on the temple to monitor physiological signals and calculate an “Entropy” metric.
- Funding profile: The venture publicly surfaced earlier this year following a $54 million fundraising round that pegged its post-money valuation at approximately $190 million.
- Investor group: Backers include Peak XV Partners, Info Edge Ventures, Steadview Capital, Dharana Capital, early Zomato backers, and startup founders.
- Testing phase: In May, Goyal confirmed that the initial batch of 100 devices was prepared for distribution to early testers, consisting of athletes, doctors, and scientists.
Why This Matters
The deal directly bolsters Temple’s clinical and scientific foundations ahead of its consumer release. Developing health-focused wearable sensors demands rigorous backing, and Temple has dedicated two years to creating sensor hardware and accumulating experimental evidence. Bringing a specialised longevity practice in-house helps validate findings and aids the startup’s current efforts to submit its scientific studies for formal peer review.
The initiative also highlights Deepinder Goyal’s shift toward high-risk technology ventures. Goyal previously stepped down from his role as chief executive of Eternal, Zomato’s parent entity, to explore ventures outside the publicly traded firm, though he retains his position as Eternal’s vice chairman.
What to Watch Next
Temple is currently pursuing peer review for its validation studies to establish the scientific credibility of its physiological tracking. Observers will also track the feedback generated by the first 100 early testers, including athletes and medical practitioners, as Temple moves toward a wider commercial debut.
Frequently Asked Questions
What does Temple make?
Temple develops a wearable technology device worn on the temple designed to measure physiological signals and track a metric termed “Entropy.”
What will happen to LongeVus clients?
LongeVus will continue operating as part of Temple, and co-founders Robert Mohr and Avi Roy will remain available to serve their existing client base.
How much was Temple valued at during its last fundraise?
Temple was valued at approximately $190 million post-money after securing $54 million from venture capital firms and angel investors earlier this year.
Source: Reported via Times of India based on statements by Deepinder Goyal and company founders.